Clinical Research Directory

Inclusion Criteria: * Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5) * Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.) * Age 18-65 * Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter) * Willingness to participate in the study (signed informed consent) Exclusion Criteria: * DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included * Psychotic disorders (though psychotic features alongside depression will be allowed) * Organic brain disease * Intelligence Quotient (IQ) \< 80 * High risk of self-harm or suicide * Current substance abuse severe level * Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study) * Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year * No other evidence-based treatment of MDD is allowed during the study. * Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.